By Y. Peter Kang (January 20, 2015, 6:01 PM EST) -- The U.S. Supreme Court refused Tuesday to hear an appeal by Teva Pharmaceuticals USA Inc. and other generic-drug makers of a ruling allowing a state failure-to-warn suit to proceed, potentially paving the way for similar cases against other generics makers.
Without providing reasoning for its decision, as is customary in its petition denials, the Supreme Court rejected Teva's bid to overturn a California appellate court's decision to let the case go forward.
In June 2013, the California Court of Appeal for the Fourth Appellate District backed a lower court's refusal to dismiss a suit claiming Teva and others failed to warn...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!